Felis ISSN 2398-2950

Ibafloxacin

Contributor(s): Linda Horspool

Introduction

Name

  • Ibafloxacin.

Class of drug

  • Fluoroquinolone antimicrobial.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Non-steroidal anti-inflammatory drugs

Use of NSAIDs in combination with ibafloxacin is contraindicated in epileptic dogs.

  • Concurrent administration of NSAIDs and fluoroquinolones potentiates CNS adverse effects in man. 

Adsorbents and antacids

  • Absorbents and antacids    Aluminum antacid   containing cations (Mg, Al) may bind fluoroquinolones, preventing their absorption from the GI tract.

Sucralfate and zinc salts

  • The absorption of fluoroquinolones may be inhibited by sucralfate   Sucralfate   and zinc salts.
    Separate doses of these drugs by at least 2 h.

Theophylline

  • Fluoroquinolones increase plasma theophylline   Theophylline   concentrations.

Cimetidine

  • The clearance of fluoroquinolones may be reduced by cimetidine   Cimetidine  .
    Caution should be exercised before using cimetidine and fluoroquinolones concomitantly.

Nitrofurantoin

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Horspool L J, van Laar P, van den Bos R & Mawhinney I C (2006)Clinical efficacy of two ibafloxacin formulations in the treatment of canine pyoderma.Vet Rec158, 236-237 PubMed.
  • Coulet M, Morello C, Cox P & Lohuis J (2005)Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats.J Vet Pharmacol Ther28(1), 29-36 PubMed.
  • Horspool L J, Laar P, Bos R & Mawhinney I (2004)Treatment of canine pyoderma with ibafloxacin and marbofloxacin - fluoroquinolones with different pharmacokinetic profiles.J Vet Pharmacol Ther27(3), 147-153 PubMed.
  • Coulet M, Van Borssum Waalkes M, Cox P, Lohuis J (2002)Invitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin.J Vet Pharmacol Ther25(6), 401-411 PubMed.
  • Coulet M, Van Borssum Waalkes M, Leeuwenkamp O R, Cox P, Lohuis J (2002)Pharmacokinetics of ibafloxacin following intravenous and oral adminstration to healthy Beagle dogs.J Vet Pharmacol Ther25(2), 89-97 PubMed.

Other sources of information


ADDED